TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05506540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 1mg
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 4mg
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 10mg
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 30mg
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg (Fed)
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 6mg QD X 14 Days
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 12mg QD X 14 Days
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg QD X 14 Days
Description: ENN0403 capsules for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral use
Study: NCT04985526

Intervention type: OTHER
Group type: OTHER
Intervention: Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
Description: Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
Description: Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
Study: NCT06032065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Treadmill Exercise
Description: This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised Treadmill Exercise
Description: This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise
Description: This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-Based Exercise
Description: This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot Juice
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot Juice
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
Study: NCT06152302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility study in dry conditions
Description: Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility study in water conditions
Description: Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
Study: NCT06131632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Description: Remove only a small part of the breast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical modified mastectomy
Description: Remove all the breast parenchyma, nipple and skin
Study: NCT04974736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEHR + Navigator
Description: The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services.
Study: NCT06301958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Description: A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
Study: NCT05656339

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO+WP
Description: Oral supplement containing carbohydrates plus whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CHO
Description: Oral supplement containing carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Fast
Description: Fast condition of 12 hours
Study: NCT04658160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients
Description: access to/use of the tracking platform
Study: NCT04571749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized handoff
Description: A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
Study: NCT06581835

Intervention type: DEVICE
Intervention: Observational
Description: The study objective requires placement of a jugular venous bulb catheter in the right or left jugular venous bulb with ultrasound guidance. A venous and radial arterial line will be placed. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
Study: NCT06523296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adults with Alzheimer's disease
Description: Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adults with Myasthenia
Description: Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healhty controls
Description: Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
Study: NCT06223711

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiochemotherapy
Description: Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy of further tumor locations
Description: Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
Study: NCT05532566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergenic extract
Description: In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
Study: NCT04998071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
Study: NCT04800965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient MyChart Scheduling Link
Description: Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient MyChart Scheduling Link
Description: Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient MyChart Scheduling Link
Description: Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient MyChart Scheduling Link
Description: Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Educational Video
Description: Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Educational Video
Description: Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Follow through Message
Description: Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Follow through Message
Description: Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
Study: NCT04789252

Intervention type: BIOLOGICAL
Intervention: Bioinformatics analysis of single cell transcriptomics data
Description: 1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry
Study: NCT05084040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90 days interval between catheter maintenance
Description: Length of time between catheter maintenances extended from 60 days to 90 days
Study: NCT04989686

Intervention type: OTHER
Intervention: Microsampling
Description: Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.

Intervention type: OTHER
Intervention: Microsampling
Description: Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.

Intervention type: OTHER
Intervention: Microsampling
Description: Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
Study: NCT05158270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Erector spinae plane block
Description: Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block
Description: Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous Multimodal Analgesia
Description: Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
Study: NCT06088862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Description: 21mg nicotine patch daily; maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Description: 21mg nicotine patch daily; maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Description: 21mg nicotine patch daily; maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Description: 21mg nicotine patch daily; maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Description: 21mg nicotine patch daily; maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette 4Mg Chewing Gum
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette 4Mg Chewing Gum
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette 4Mg Chewing Gum
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette 4Mg Chewing Gum
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette 4Mg Chewing Gum
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Lozenge Product
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Lozenge Product
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Lozenge Product
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Lozenge Product
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Lozenge Product
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIDI e-cigarette
Description: BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on!
Description: 4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks
Study: NCT05419583

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography
Description: CT scan of the heart arteries

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography
Description: Invasive coronary angiography via the radial or femoral approach
Study: NCT05939141

Intervention type: DEVICE
Intervention: Genio System
Description: All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy.
Study: NCT05419583

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Ultrasound scan of the heart

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI scan
Description: An MRI scan to assess the heart structure and function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug (Aspirin or Statin)
Description: Antiplatelet therapy for coronary artery disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)
Description: Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline directed heart failure therapy
Description: Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
Study: NCT06231381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Anti-IL-36R antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-biologically active drug
Study: NCT04744675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
Study: NCT06048133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab IV: Day 1 and 22 every 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Quemliclustat IV: Day 1, 15, 29 every 42 days